Researchers at the Amsterdam University Medical Centers (UMC) have created a Dutch version of the Balance Retraining interactive website and researched its effectiveness. This builds on the success of an English version of the site which has been running for over two years—helping 3,500 patients to date.
“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection," said Kathie Bishop, PhD, chief scientific officer of Otonomy.
A presentation demonstrating the therapeutic potential of OTO-413, a sustained-exposure otic formulation of brain-derived neurotrophic factor (BDNF), for the repair of cochlear synaptopathy in speech-in-noise hearing difficulties has been selected by SfN as a Neuroscience 2018 Hot Topic.
The Baha SoundArc was designed to provide children with conductive hearing loss, mixed hearing loss, or single-sided sensorineural deafness (SSD) with the hearing performance and amplification they need to facilitate language development on par with their hearing peers.
Read More
To refute common misconceptions that it only affects older adults, HHF has collected images of individuals living with a hearing condition to capture the diversity of its impact across the country.
Read More
Otonomy intends to complete the clinical development to support registration of OTIVIDEX in the United States for patients with Ménière’s disease, and will advance multiple programs for the prevention and treatment of sensorineural hearing loss, and the treatment of tinnitus.
Read More
The measurement of subjective visual vertical (SVV) can serve as a diagnostic indicator of utricular otolith (dys)function, and involves an individual’s ability to adjust a vertical line to be parallel with gravity in the absence of visual cues.
Read More
Otonomy, Inc. announced a set of immediate actions to preserve capital, extend its cash runway, and build shareholder value following the recent negative AVERTS-1 Phase 3 trial results for OTIVIDEX in Ménière’s disease.
Read More
The clinical trial missed its primary endpoint which was the count of definitive vertigo days by Poisson Regression analysis (p=0.62).
Read More
SPI-1005, an investigational new drug that mimics and induces Glutathione Peroxidase (GPx), has been shown to reduce the swelling or edema of the inner ear in animal studies involving acoustic trauma.
Read More
The meeting will feature presentations by opinion leaders Paul R. Lambert, MD, and Anthony A. Mikulec, MD, MBA, who will discuss the significant disease burden and unmet medical needs in the treatment of Ménière’s disease, review the OTIVIDEX™ Phase 2b clinical trial results, and share their clinical trial experience using OTIVIDEX.
Read More
Auris Medical Holding AG and Otonomy Inc are set to release late-stage data from drug trials on treatments that could be used for tinnitus and Ménière’s disease, according to an article in Reuters.
Read More
Auris Medical will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Ménière’s disease and vestibular vertigo. The company also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) for acute and post-acute inner ear tinnitus.
Read More
Scientists at Imperial College in London have found that injections of the steroid methylprednisolone, given through the ear drum to treat balance problems associated with Ménière’s disease, are as effective as the current ‘gold standard’ treatment of antibiotic injections, with fewer side effects.
Read More
Dr Desmond explains when the drug Meclizine is helpful for dizziness, and when it should be withdrawn in favor of other therapies. He also covers why it is not recommended for complaints of lightheadedness, loss of balance, and other symptoms or conditions.
Read More
A January 9, 2015 New York Times article reviews pharmaceutical companies’ pursuit of drug therapies for ear and balance ailments, including hearing loss, tinnitus, vertigo.
Read More
Researchers at the University of Exeter Medical School have been able to suggest what goes wrong in the body when people develop Ménière’s disease, and provide new insight into factors that lead to its development.
Read More